CAPR
HealthcareCapricor Therapeutics, Inc. · Biotechnology · $1B
What is Capricor Therapeutics, Inc.?
Capricor Therapeutics is a clinical-stage biotechnology company based in San Diego, California, focused on developing cell and exosome-based therapies for serious diseases. Its pipeline targets conditions with limited treatment options, including Duchenne muscular dystrophy.
Capricor generates no commercial revenue yet — it advances investigational therapies through clinical and pre-clinical trials. Its lead program, CAP-1002, is an allogeneic cardiac-derived cell therapy that has completed a Phase III trial for late-stage Duchenne muscular dystrophy. The company also explores exosome-based platforms and vaccine candidates. Manufacturing for CAP-1002 is conducted in collaboration with Lonza Houston, Inc., a key external partner supporting clinical-stage production.
Founded in 2007 and headquartered in San Diego, California.
- CAP-1002: allogeneic cell therapy for Duchenne muscular dystrophy
- CAP-1002: Phase II evaluation for cytokine storm in SARS-CoV-2
- CAP-2003: pre-clinical exosome therapy for trauma-related conditions
- COVID-19 vaccine candidates in early development
Is CAPR a Good Stock to Buy?
UQS Score rates CAPR as Poor overall, reflecting the early-stage nature of the business across nearly every dimension evaluated.
Among the five pillars, Risk is the one area rated Neutral — suggesting the company's risk profile is not extreme relative to other clinical-stage peers, which is notable given the inherent uncertainty of pre-revenue biotech.
Quality, Moat, and Growth all carry Weak ratings, consistent with a company that has no commercial products, no established competitive advantages, and an unproven revenue model. Valuation is rated Elevated, meaning the current market price appears to reflect significant optimism relative to fundamentals.
See the full pillar breakdown and detailed financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CAPR pay dividends?
No — Capricor Therapeutics, Inc. does not currently pay a dividend.
Capricor Therapeutics does not pay a dividend. As a clinical-stage company with no commercial revenue, capital is directed toward research, clinical trials, and pipeline advancement rather than shareholder distributions. Income-focused investors should be aware that dividends are unlikely until the company reaches commercial-stage operations.
When does CAPR report earnings?
Capricor Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly reports focus on cash runway, operating expenses, and pipeline milestones rather than sales or profit figures. Trial updates and regulatory developments tend to be the most market-moving disclosures.
For the most recent quarter's results and pipeline updates, visit Capricor Therapeutics' investor relations page.
CAPR Price History
+832.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Capricor Therapeutics, Inc.?
Based on Capricor Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CAPR Long-term Outlook
With Growth and Quality both rated Weak, Capricor's near-term fundamental outlook is heavily dependent on clinical trial outcomes rather than organic business expansion. The Neutral Risk rating provides a modest counterbalance, but the Elevated Valuation label suggests the market may already be pricing in a favorable scenario. Investors should weigh pipeline binary events carefully against the current price.
Growth drivers
- Potential regulatory progress for CAP-1002 in Duchenne muscular dystrophy
- Expansion of exosome-based platform into additional indications
- Partnership or licensing opportunities leveraging the Lonza manufacturing collaboration
Key risks
- Clinical trial failure or regulatory setbacks for lead candidate CAP-1002
- Elevated valuation leaves limited margin of safety if milestones are missed
- Ongoing cash burn with no commercial revenue to offset operating costs
CAPR vs Peers
Capricor operates in a competitive clinical-stage biotech landscape alongside other small-cap companies pursuing novel therapeutic platforms.
Immunocore focuses on T-cell receptor bispecific therapies and has achieved commercial-stage status with an approved oncology product, distinguishing it from earlier-stage peers.
Ardelyx develops small-molecule therapies targeting gastrointestinal and kidney conditions, and has transitioned into a commercial-stage company with approved products on the market.
Taysha pursues gene therapy for rare neurological diseases, sharing Capricor's clinical-stage risk profile but operating in a distinct modality and disease area.
Frequently Asked Questions
What does Capricor Therapeutics do?
Capricor Therapeutics is a clinical-stage biotech developing cell and exosome-based therapies. Its lead program, CAP-1002, targets late-stage Duchenne muscular dystrophy and has completed a Phase III trial. The company also has earlier-stage programs in trauma and infectious disease.
Does CAPR pay dividends?
No, Capricor Therapeutics does not pay a dividend. The company is pre-revenue and directs all available capital toward clinical development and operations. Dividend payments are not expected until the company reaches a commercial stage.
When does CAPR report earnings?
Capricor Therapeutics reports on a quarterly basis, as required for US-listed public companies. For exact dates and the most recent financial disclosures, check the investor relations section of the company's official website.
Is CAPR a good stock to buy?
UQS Score rates CAPR as Poor, driven by Weak ratings across Quality, Moat, and Growth, alongside an Elevated Valuation. This profile reflects the high-risk, pre-revenue nature of clinical-stage biotech investing. The full pillar breakdown is available to UQS Pro members.
Is CAPR overvalued?
The UQS Valuation pillar for CAPR is rated Elevated, suggesting the current market price may reflect optimistic assumptions about pipeline success. For a clinical-stage company with no commercial revenue, valuation is largely driven by trial outcomes and market sentiment.
How does CAPR compare to its competitors?
Compared to peers like Immunocore and Ardelyx — both of which have reached commercial-stage status — Capricor remains earlier in its development journey. Against Taysha Gene Therapies, Capricor shares a similar clinical-stage risk profile but pursues a different therapeutic modality.
What is CAPR's market cap bracket?
Capricor Therapeutics is classified as a small-cap company. This places it among smaller publicly traded biotechs, where liquidity and volatility can be more pronounced than in large- or mega-cap peers.
Who founded Capricor Therapeutics?
Capricor Therapeutics was founded in 2007. Detailed founding history, including the names of founders, is publicly available through the company's official disclosures and investor relations materials.
Is CAPR a long-term quality investment?
As a long-term quality indicator, UQS rates CAPR as Poor. Weak scores across Quality, Moat, and Growth suggest the company has not yet established the durable fundamentals typically associated with long-term investment quality. Clinical milestones could change this picture over time.
What is the main competitive advantage of Capricor Therapeutics?
Capricor's differentiation lies in its cell and exosome-based platform, which is a relatively novel therapeutic modality. However, the UQS Moat pillar is rated Weak, reflecting that no durable commercial advantage has been established at this stage of development.
What sector does CAPR belong to?
Capricor Therapeutics operates in the Healthcare sector, specifically within clinical-stage biotechnology. Companies in this segment are typically pre-revenue and carry higher binary risk tied to regulatory and clinical trial outcomes.
Is CAPR a growth stock or value stock?
Based on UQS pillar labels, CAPR does not fit neatly into either category. The Growth pillar is rated Weak given the absence of commercial revenue, while the Valuation pillar is Elevated — making it neither a traditional growth nor value play by fundamental measures.
Unlock Full CAPR Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare CAPR against sector peers side by side
- ✓Track pipeline risk signals within the Risk pillar
- ✓Get the full analyst-grade view for Pro members
Pro Analysis
CAPR — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | 10.5 | 0.0 | 11.0 | 0.0 | 51.4 | 0.0 | — |
CAPR — Pillar Breakdown
Quality
— 0.0/100 (25%)Capricor Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Capricor Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 51.4/100 (15%)Capricor Therapeutics, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Capricor Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Capricor Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CAPR.
Score Composition
Financial Data
More Stock Analysis
How is the CAPR UQS Score Calculated?
The UQS (Unified Quality Score) for Capricor Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Capricor Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Capricor Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.